Clinical Features of Distant Lymph Node Metastasis in Early-Stage Extranodal Nasal-Type NK/T-cell Lymphoma after Treatment

陈波,李晔雄,刘清峰,王维虎,金晶,王淑莲,刘跃平,宋永文,房辉

DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2014.03.002

2014-01-01

Abstract:Objective To analyze the incidence and risk factors for distant lymph node metastasis in stage Ⅰ E and Ⅱ E upper aerodigestive tract natural killer (NK)/T-cell lymphoma (UADT-NKTCL) after treatment.Methods From December 1979 to December 2012,468 patients with stage Ⅰ E and Ⅱ E UADTNKTCL were treated; 170 patients were treated with radiotherapy alone,19 patients with chemotherapy alone,278 patients with radiotherapy and chemotherapy,and one patient with anti-inflammation therapy.The incidence of distant lymph node metastasis was calculated by the Kaplan-Meier method.Results The median follow-up was 35 months.Thirty-two patients had distant lymph node metastasis,accounting for 6.8％ of all patients and 19.8％ of 162 patients who had disease progression or recurrence; the 2-year incidence of distant lymph node metastasis was 6.4％.Twenty-three (71.9％) of the 32 patients had distant organ metastasis.Mesenteric lymph nodes were most affected in distant lymph node metastasis.The univariate analysis showed that extranasal UADT-NKTCL,stage Ⅱ E,and not achieving a complete response (non-CR) after the first course of treatment were high-risk factors for distant lymph node metastasis.The multivariate analysis showed that stage ⅡE and non-CR after the first course of treatment were identified as independent risk factors for long-term recurrence,with hazard ratios of 2.82 (1.37-5.82,P =0.005) and 3.01 (1.16-7.78,P =0.023).For patients with stage Ⅱ E disease,those receiving combined-modality therapy had a significantly lower incidence of distant lymph node metastasis than those receiving radiotherapy alone and chemotherapy alone (2-year incidence of distant lymph node metastasis:12.5％ vs 35.1％ and 50.0％,P =0.011).Conclusions The incidence of distant lymph node metastasis is low in patients with stage Ⅰ E and Ⅱ E UADT-NKTCL after treatment.However,the patients with stage Ⅱ E disease or nonCR after the first course of treatment still have a high risk of distant lymph node metastasis.Patients with stage Ⅱ E UADT-NKTCL should be treated by combined-modality therapy to reduce the incidence of distant lymph node metastasis.